- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 23, 2013 | 10:19 AM EDT
We'll add to this tech position, a big-box retailer and our newest bank holding. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 22, 2013 | 10:27 AM EDT
The stock has doubled over the past three months and we don't want to be greedy with our gains. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 23, 2013 | 01:40 PM EDT
Expectations demand that the company meet consensus estimates and at least maintain its guidance. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Vivus (VVUS)
VVUS (NASDAQ:Drugs)
$14.28
+0.76
+5.62%
Today's Range: 13.12 - 14.52 |
VVUS Avg Daily Volume: 2,477,100
| Last Update: 05/23/13 - 2:00 PM EDT |
| Volume: 3,668,866 |
| YTD Performance: -1.94% |
| Open: $13.40 |
| Previous Close: $13.52 |
| 52 Week Range: $9.86 - $31.21 |
| Oustanding Shares: 100,665,029 |
| Market Cap: 1,324,751,782 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 5 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 |
| Moderate Sell | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 |
| Mean Rec. | 2.40 | 2.27 | 2.17 | 2.27 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $-0.49 | $-0.20 | $-1.91 | $-0.95 |
| Number of Analysts | 6 | 5 | 7 | 6 |
| High Estimate | $-0.42 | $0.54 | $-1.06 | $0.03 |
| Low Estimate | $-0.58 | $-0.59 | $-2.41 | $-1.81 |
| Prior Year | $-0.24 | $-0.40 | $-1.42 | $-1.91 |
| Growth Rate (Year over Year) | -104.17% | 50.50% | -34.21% | 50.15% |
NoanetTrader: $VVUS could be worth a shot on a pop over this level
2 minutes ago from StockTwits Web
2 minutes ago from StockTwits Web
kenfrombarbados: RT @StockkyTrading: Who Wants A Free 1 Week Trial To SFB Trading Room?
First 5 Retweets
$CRUS
$GME
$HPQ
$MNKD
$SPY
$VVUS
$CSIQ
$EWJ
$HK
$BTU
$LOGI
$HLF
$AMPE
25 minutes ago from web
25 minutes ago from web
coffee_junkies: RT @A_Karunaratne: @fredmartin121
Not a fan of $VVUS, don't believe in their ponzi scheme. Not a novel drug but formulation of 2 drugs that failed & docs hate
40 minutes ago from Twitter for iPhone
40 minutes ago from Twitter for iPhone
HiBetaSpreads: $VVUS is SHORT of the year! We just filled out short position at $14.25! I look for -25% move by Q2 earnings report in Aug, -50% by year-end
45 minutes ago from TweetCaster for Android
45 minutes ago from TweetCaster for Android
StocksGator: $VVUS Cup with handle breakout today. Buy Point was 14.07. Volume supporting move.
55 minutes ago from StockTwits Web
55 minutes ago from StockTwits Web
mulla101: "@paulwoll: $LPSN $VVUS $IMMR - Some bullish MACD cross plays w/ long setups."@OadayDay
1 hour ago from Twitter for Android
1 hour ago from Twitter for Android
teevee: "@NoanetTrader: $VVUS flag failing, if it doesnt bounce here, I will bail"
1 hour ago from StockTwits Web
1 hour ago from StockTwits Web
Vivus downgraded at Lazard
VVUS was downgraded from Buy to Neutral, Lazard Capital Markets said. The window of opportunity is closing for Qsymia in the obesity market.
Vivus estimates, target reduced at JMP
Shares of VVUS now seen reaching $30, according to JMP Securities. Estimates also cut, given lower expected Qsymia sales. Outperform rating.
Vivus added to US 1 List at BofA/Merrill
VVUS was added to the US 1 list, according to Bank of America/Merrill Lynch said. $30 price target. Retail distribution approval should boost Qsymia sales.
Vivus estimates, target reduced at Lazard
Shares of VVUS now seen reaching $27, according to Lazard. Estimates also cut, given a sluggish expected launch for Qysmia. Buy rating.
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Jim Cramer says we should throw out the ADP report and the BLS should out source the work to TIBCO.
Vivus target reduced at Credit Suisse
Shares of VVUS now seen reaching $29, according to Credit Suisse. EU may not approve Qsymia. Outperform rating.
Adam Feuerstein, Sr. Columnist for TheStreet, says obesity drugs are the next big thing to watch in biotech.
Vivus upgraded at Lazard
VVUS was upgraded to Buy, Lazard said. New analyst has a $36 price target. Obesity drug should drive growth over the next several quarters.
Adam Feuerstein, Sr. Columnist for TheStreet, says post FDA approval trading is the next big thing to watch in biotech.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.